HL Financial Services’s United Therapeutics UTHR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q1
$200K Sell
1,701
-152
-8% -$17.7K ﹤0.01% 709
2018
Q4
$202K Sell
1,853
-1,471
-44% -$171K ﹤0.01% 690
2018
Q3
$425K Buy
3,324
+613
+23% +$75.8K 0.01% 573
2018
Q2
$307K Buy
2,711
+658
+32% +$72.3K 0.01% 574
2018
Q1
$231K Buy
2,053
+589
+40% +$74.8K ﹤0.01% 647
2017
Q4
$217K Buy
+1,464
New +$186K ﹤0.01% 572
2017
Q1
Sell
-3,535
Closed -$507K 697
2016
Q4
$507K Sell
3,535
-385
-10% -$49.2K 0.01% 439
2016
Q3
$463K Sell
3,920
-80
-2% -$9.61K 0.01% 439
2016
Q2
$424K Buy
4,000
+104
+3% +$11.6K 0.01% 465
2016
Q1
$434K Buy
3,896
+80
+2% +$10.1K 0.01% 458
2015
Q4
$598K Buy
3,816
+160
+4% +$23.3K 0.02% 406
2015
Q3
$480K Sell
3,656
-61
-2% -$9.78K 0.01% 433
2015
Q2
$647K Buy
3,717
+7
+0.2% +$1.26K 0.02% 403
2015
Q1
$640K Sell
3,710
-14
-0.4% -$2.13K 0.02% 404
2014
Q4
$482K Sell
3,724
-119
-3% -$15.3K 0.01% 448
2014
Q3
$494K Buy
+3,843
New +$396K 0.01% 417

Other funds holding UTHR

HL Financial Services's UTHR Position: Q1 2019 in Review

HL Financial Services reduced its United Therapeutics (UTHR) stake by 8.2% in Q1 2019, selling an estimated $17.7K and leaving 1,701 shares worth $200K. The position accounts for ﹤0.01% of the portfolio, ranked #709.

HL Financial Services first reported a position in UTHR in Q3 2014 and has held it in 16 quarters since. The position peaked at $647K in Q2 2015. 378 funds tracked by Wall St. Rank hold UTHR as of Q1 2019.

  • HL Financial Services held 1,701 shares of United Therapeutics worth $200K as of Q1 2019.
  • HL Financial Services sold 152 United Therapeutics shares in Q1 2019, an estimated $17.7K.
  • United Therapeutics made up ﹤0.01% of HL Financial Services's portfolio in Q1 2019, its #709 holding.
  • HL Financial Services first reported a position in United Therapeutics in Q3 2014 and has held it in 16 quarters since.
  • HL Financial Services's United Therapeutics position peaked at $647K in Q2 2015.
  • 378 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2019.

Based on HL Financial Services's 13F filing for Q1 2019, filed 1 May 2019.